Cite this: Rasagiline: A Second-Generation Monoamine Oxidase Type-B Inhibitor for the Treatment of Parkinson's Disease - Medscape - May 15, 2006.

Rasagiline: A Second-Generation Monoamine Oxidase Type-B Inhibitor for the Treatment of Parkinson's Disease Jack J. Chen; Anh-Vuong Ly Disclosures Am J Health Syst Pharm. 2006;63 (10):915-928.

Those on medications like monoamine oxidase inhibitors (MAOIs) need to be extremely cautious due to the risk of interaction with tyramine, which is high in fermented foods.” — Johannah Katz ...

These 11 everyday foods can interfere with common medications—learn what to avoid and how to protect your health.

Valium (diazepam) was brought to the market by Roche in 1963, followed by the introduction of the monoamine oxidase inhibitor (MAOI) class of anti-depressants and antipsychotic haloperidol.

Are allergic to Zoloft or any of its ingredients. If you're unsure, ask your pharmacist or healthcare provider for a complete list of the ingredients. Are taking, or within 14 days of stopping, a ...

Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD ...

Gross proceeds from offering total $16.6 million. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and ...

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...